LeJeune Puetz Investment Counsel LLC maintained its stake in shares of Novartis AG (NYSE:NVS) during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 7,100 shares of the company’s stock at the end of the second quarter. LeJeune Puetz Investment Counsel LLC’s holdings in Novartis AG were worth $593,000 as of its most recent SEC filing.

Other hedge funds have also recently modified their holdings of the company. City Holding Co. raised its stake in shares of Novartis AG by 4.6% in the second quarter. City Holding Co. now owns 1,217 shares of the company’s stock valued at $102,000 after buying an additional 54 shares during the last quarter. Howe & Rusling Inc. raised its stake in shares of Novartis AG by 192.2% in the first quarter. Howe & Rusling Inc. now owns 1,341 shares of the company’s stock valued at $100,000 after buying an additional 882 shares during the last quarter. TCI Wealth Advisors Inc. raised its stake in shares of Novartis AG by 20.0% in the first quarter. TCI Wealth Advisors Inc. now owns 1,381 shares of the company’s stock valued at $103,000 after buying an additional 230 shares during the last quarter. Archford Capital Strategies LLC raised its stake in shares of Novartis AG by 72.3% in the first quarter. Archford Capital Strategies LLC now owns 1,480 shares of the company’s stock valued at $110,000 after buying an additional 621 shares during the last quarter. Finally, Kernodle & Katon Asset Management Group LLC raised its stake in shares of Novartis AG by 3.4% in the first quarter. Kernodle & Katon Asset Management Group LLC now owns 1,488 shares of the company’s stock valued at $111,000 after buying an additional 49 shares during the last quarter. 11.27% of the stock is owned by institutional investors.

Shares of Novartis AG (NYSE:NVS) traded down 0.75% during trading on Thursday, hitting $83.55. The stock had a trading volume of 566,597 shares. The firm has a market cap of $195.75 billion, a P/E ratio of 30.50 and a beta of 0.73. The firm has a 50 day moving average price of $84.23 and a 200 day moving average price of $78.55. Novartis AG has a 12-month low of $66.93 and a 12-month high of $86.90.

Novartis AG (NYSE:NVS) last posted its earnings results on Tuesday, July 18th. The company reported $1.22 EPS for the quarter, beating the Zacks’ consensus estimate of $1.16 by $0.06. Novartis AG had a return on equity of 15.51% and a net margin of 13.52%. The firm had revenue of $12.24 billion for the quarter, compared to analysts’ expectations of $12.20 billion. During the same period last year, the firm earned $1.23 EPS. The company’s quarterly revenue was down 1.8% on a year-over-year basis. On average, equities analysts expect that Novartis AG will post $4.73 earnings per share for the current fiscal year.

WARNING: “LeJeune Puetz Investment Counsel LLC Has $593,000 Position in Novartis AG (NVS)” was first published by Watch List News and is the property of of Watch List News. If you are viewing this news story on another site, it was stolen and reposted in violation of international trademark & copyright law. The original version of this news story can be read at https://www.watchlistnews.com/lejeune-puetz-investment-counsel-llc-has-593000-position-in-novartis-ag-nvs/1471133.html.

Several analysts recently commented on the company. UBS AG reaffirmed a “neutral” rating on shares of Novartis AG in a report on Tuesday, May 30th. Cowen and Company set a $90.00 price objective on Novartis AG and gave the stock a “hold” rating in a report on Wednesday. J P Morgan Chase & Co reaffirmed a “neutral” rating on shares of Novartis AG in a report on Thursday, June 8th. BidaskClub raised Novartis AG from a “sell” rating to a “hold” rating in a report on Saturday, August 5th. Finally, TheStreet upgraded Novartis AG from a “c+” rating to a “b” rating in a research report on Friday, June 2nd. Three investment analysts have rated the stock with a sell rating, ten have issued a hold rating and six have issued a buy rating to the company. Novartis AG currently has a consensus rating of “Hold” and a consensus price target of $83.56.

In other Novartis AG news, major shareholder Bioventures Ltd Novartis bought 266,667 shares of the company’s stock in a transaction dated Wednesday, July 5th. The shares were purchased at an average cost of $15.00 per share, for a total transaction of $4,000,005.00. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 0.01% of the stock is owned by company insiders.

About Novartis AG

Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.

Want to see what other hedge funds are holding NVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novartis AG (NYSE:NVS).

Institutional Ownership by Quarter for Novartis AG (NYSE:NVS)

Receive News & Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related companies with Analyst Ratings Network's FREE daily email newsletter.